Unlocking Magnetic Superpowers: Mn5Ge3’s Topological Magnons
In the ever-evolving landscape of condensed matter physics, a recent breakthrough has emerged from the collaborative efforts of researchers at the Peter Grünberg Institute ...
Page Content
-
-
Next Milestone for JUPITER – High-Tech Base for the European Exascale Supercomputer
Construction of the first European exascale supercomputer JUPITER at Forschungszentrum Jülich is making progress. Forschungszentrum Jülich and Eviden (Atos Group) have signed a contract ...
-
Higher measurement accuracy opens new window to the quantum world
A team at HZB from Helmholtz Information has developed a new measurement method that, for the first time, accurately detects tiny temperature differences in ...
-
Helmholtz GPU Hackathon 2024: Registration Is Open!
Together with NVIDIA and the OpenACC organization, Helmholtz will host a hybrid Open Hackathon taking place on six days in total: on April 8 ...
-
Metals for the future
Components for cars and airplanes should be even lighter and more robust in the future – to save fuel and reduce CO2 emissions. This ...
-
Advanced Molecular Simulations On JUWELS Booster Pave The Way For Future HIV-1 Treatments
In the fight against the enigmatic HIV-1 virus, a recent study reveals a turning point: the discovery of the virus’s Achilles’ heel, which could ...
-
EBRAINS research infrastructure secures €38 million in funding for new phase of digital neuroscience
Helmholtz Information congratulates: The European Commission has signed a grant agreement to fund EBRAINS with €38 million until 2026. Over the next three years, ...
-
Elevating our Understanding of Inner Ear Sound Amplification
Our ability to detect different sounds intensities and pitches with great sensitivity is largely due to the inner ear’s ability to decode sound waves ...
-
Game-changer in material science
DurAMat aims to accelerate the slow uptake of new and sustainable additively manufactured materials across a wide range of industries – from the energy ...
-
Alzheimer’s Drug PRI-002 Receives EMA Approval for Phase II Trial
The Alzheimer’s drug candidate PRI-002 is entering the next clinical trial phase: the European Medicines Agency (EMA) has granted approval to conduct a phase ...